Sun Pharmaceutical Industries Ltd. 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093 India

Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

Sun Pharma to announce second quarter results on November 13, 2013

October 28, 2013, Mumbai: On November 13, 2013, Sun Pharma will announce results for the second quarter & half year ending September 30, 2013. These results will also be available on the Company website, www.sunpharma.com.

Earnings call (10.30 am IST, November 14, 2013)

The Company will conduct an hour long call at 10.30 am IST on November 14, 2013 where senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.

Summary of events

Event	Date and time	Telephone number/ website
Earnings release	November 13, 2013	www.sunpharma.com
Earnings	10.30 am IST,	Primary Number: +91 22 6629 0088
conference call	November 14, 2013	Secondary Number: +91 22 3065 0088
		Via audio webcast, details of which will be made available
		on <u>www.sunpharma.com</u> .
Replay of	November 15, 2013 to	India: +91 22 3065 1212.
conference call	November 22, 2013	ID: #786742
		Via audio webcast playback, details of which will be made available on www.sunpharma.com.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international specialty pharmaceutical company with over 72% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world. For the year ending March 2013, overall revenues were at US\$2.1 billion, of which US contributed US\$1.1 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex dosage forms. More information about the company can be found at www.sunpharma.com.

Sun Pharmaceutical Industries Ltd. 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093 India

Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685



Contacts

Nimish Desai

Tel +91 22 6645 5645, Xtn 717 Tel Direct +91 22 66455717

Tel Direct +91 22 66455717 Mobile +91 98203 30182

E mail <u>nimish.desai@sunpharma.com</u>

Mira Desai

Tel +91 22 6645 5645, Xtn 606

Tel Direct +91 22 66455606 Mobile +91 98219 23797

E mail <u>mira.desai@sunpharma.com</u>